Özer Ömer, Baysal Zeki, Yildirim Biçer Gamze, Doğan Levent
Department of Ophthalmology, Niğde Ömer Halisdemir University, Niğde, Turkey.
J Glaucoma. 2025 Mar 1;34(3):224-231. doi: 10.1097/IJG.0000000000002520. Epub 2024 Nov 27.
Treatment with LBN ophthalmic solution 0.024% reduced IOP by an average of 29.9% and 31.8% in patients with POAG and PXG, respectively, and improved VD in different quadrants in all slabs. Therefore, the importance of LBN in the treatment of glaucoma is likely to be that it increases macular microcirculation, possibly through NO, independent of its IOP-reducing effect.
The aim of this study was to investigate the effect of topical latanoprostene bunod 0.024% applied once daily on intraocular pressure and macular vessel density in newly diagnosed primary and pseudoexfoliative open angle glaucoma patients.
A total of 66 patients with newly diagnosed open angle glaucoma were included in this study (group 1). Thirty-four patients had primary (POAG, group 1A) and 32 patients had secondary (pseudoexfoliative glaucoma, PXG, group 1B) open angle glaucoma. Thirty-two healthy participants (group 2) were included in this single-center, prospective study.
In group 1, the mean IOP decrease in first month of treatment with LBN was 7.7 mm Hg and IOP change was -30.8%. In the superficial slab, the vessel density (VD) in the superior and nasal quadrants was lower in group 1B compared with group 1A in the first month of treatment ( P =0.038, 0.019, respectively). In the choriocapillaris slab, the VD in the superior quadrant at baseline (before treatment) was statistically lower in both groups compared with the VD in the superior quadrant in the first month of treatment ( P <0.001, for both).
In conclusion, treatment with LBN ophthalmic solution 0.024% reduced IOP by an average of 29.9% and 31.8% in patients with POAG and PXG, respectively, and improved VD in different quadrants in all slabs. Therefore, the importance of LBN in the treatment of glaucoma is likely to be that it increases macular microcirculation, possibly through NO, independent of its IOP-reducing effect.
0.024%的拉坦前列素倍他米松眼用溶液治疗原发性开角型青光眼（POAG）和假性剥脱性青光眼（PXG）患者时，分别使眼压平均降低29.9%和31.8%，并改善了所有层面不同象限的血管密度（VD）。因此，拉坦前列素倍他米松在青光眼治疗中的重要性可能在于它增加了黄斑微循环，可能是通过一氧化氮（NO）实现的，与其降低眼压的作用无关。
本研究旨在探讨每日一次应用0.024%的曲伏前列素滴眼液对新诊断的原发性和假性剥脱性开角型青光眼患者眼压和黄斑血管密度的影响。
本研究共纳入66例新诊断的开角型青光眼患者（第1组）。34例为原发性开角型青光眼（POAG，第1A组），32例为继发性开角型青光眼（假性剥脱性青光眼，PXG，第1B组）。32名健康参与者（第2组）纳入了这项单中心前瞻性研究。
在第1组中，使用拉坦前列素倍他米松治疗的第一个月平均眼压降低7.7 mmHg，眼压变化为-30.8%。在治疗的第一个月，在浅表层面，第1B组上象限和鼻侧象限的血管密度（VD）低于第1A组（P分别为0.038和0.019）。在脉络膜毛细血管层面，两组治疗前基线时上象限的血管密度与治疗第一个月时上象限的血管密度相比，差异均有统计学意义（两组P均<0.001）。
总之，0.024%的拉坦前列素倍他米松眼用溶液治疗POAG和PXG患者时，分别使眼压平均降低29.9%和31.8%，并改善了所有层面不同象限的血管密度。因此，拉坦前列素倍他米松在青光眼治疗中的重要性可能在于它增加了黄斑微循环，可能是通过一氧化氮（NO）实现的，与其降低眼压的作用无关。
